Annual Report

Overview

The report presents Windlas Biotech's FY2023-24 performance, including consolidated revenue from operations of INR 6,309.56 million and consolidated profit for the year of INR 581.87 million. It highlights commissioning of the Plant V injectable facility and a workforce of 1,154 permanent employees. CSR expenditure totaled INR 9.93 million across healthcare, education, animal welfare and environmental sustainability. The report also describes quality, health, safety and environmental controls across its manufacturing operations.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2023-2024
Period: 1 April 2023 – 31 March 2024
Publication date: 9 September 2024
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services